We are live on ! Find out more
CRKN

Crown Electrokinetics Corp. Common Stock
CRKN

Delisted

CRKN was delisted on the 4th of March, 2025.

Back to rankings

8 hedge funds and large institutions have $17.1K invested in Crown Electrokinetics Corp. Common Stock in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

14% more funds holding

Funds holding: 7 → 8 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

82% less capital invested

Capital invested by funds: $96.8K → $17.1K (-$79.7K)

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$4.65K
2
UBS Group
UBS Group
Switzerland
+$4.65K
3
CSS
Cubist Systematic Strategies
Connecticut
+$2.32K
4
HF
HRT Financial
New York
+$2.32K
5
Jane Street
Jane Street
New York
+$2.32K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$30K
2
VF
Virtu Financial
New York
-$18.6K
3
Citadel Advisors
Citadel Advisors
Florida
-$11.9K
4
JP Morgan Chase
JP Morgan Chase
New York
-$6.48K
5
TSS
Two Sigma Securities
New York
-$5.59K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$3K -$18.6K -8 -80%
HF
2
HRT Financial
New York
$3K +$2.32K +1 +100%
UBS Group
3
UBS Group
Switzerland
$2.7K +$4.65K +2 New
Goldman Sachs
4
Goldman Sachs
New York
$2.42K +$4.65K +2 New
CSS
5
Cubist Systematic Strategies
Connecticut
$1.25K +$2.32K +1 New
Jane Street
6
Jane Street
New York
$1.14K +$2.32K +1 New
Two Sigma Advisers
7
Two Sigma Advisers
New York
$815 – – –
JF
8
Jump Financial
Illinois
$732 +$2.32K +1 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$613 – – –
TRCT
10
Tower Research Capital (TRC)
New York
$567 – – –
ACA
11
American Capital Advisory
Idaho
$539 – – –
Morgan Stanley
12
Morgan Stanley
New York
$166 – – –
BCWM
13
Bartlett & Co Wealth Management
Ohio
$120 – – –
Wells Fargo
14
Wells Fargo
California
$14 – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$10 – – –
BlackRock
16
BlackRock
New York
$1 – – –
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$30K -9 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$11.9K -4 Closed
JP Morgan Chase
19
JP Morgan Chase
New York
– -$6.48K -2 Closed
TSS
20
Two Sigma Securities
New York
– -$5.59K -2 Closed

CRKN Hedge Fund Activity: Q1 2024 in Review

8 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Crown Electrokinetics Corp. Common Stock (CRKN) for Q1 2024, worth a combined $17.1K — down 82% from $96.8K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CRKN positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $4.65K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $30K sold.

  • 8 institutional investors held Crown Electrokinetics Corp. Common Stock (CRKN) as of Q1 2024, up from 7 in Q4 2023.
  • Funds reported $17.1K of Crown Electrokinetics Corp. Common Stock stock for Q1 2024, down 82% quarter-over-quarter.
  • 5 funds opened new Crown Electrokinetics Corp. Common Stock positions in Q1 2024 and 4 closed out, a net change of +1 holder.
  • The largest Crown Electrokinetics Corp. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $4.65K added.
  • The largest Crown Electrokinetics Corp. Common Stock seller in Q1 2024 was Acadian Asset Management, an estimated $30K sold.

Based on aggregated 13F filings for Q1 2024.